The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
That stood out to me too CO, I’m pleased it’s something they’ve been working on and pleased with with a reputable company with a proven product. All the noises from govt that we’ve previously heard correlate with Awacta’s test being the holy grail.
As for the current share price... 137p... never thought I’d see that ******* **** again. Wilson! Hopefully the last ever time. It’s a shame as having added on yesterday’s madness I’m skint so can’t add more today. It’s crazy the price has moved down based on such confident statements from Sir Al regarding the potential. 120m per month was a dream figure and now we’re hearing conversations (strictly confidential ones) are happening to put Awacta at the heart of Moonshot. That’s easily worth billions. Finncap have said up to £8 on currently capacity of 5-10m a month.
It’s a great summary Chiron, thank you, and very prescient point about near-term “share price mischief”!
One of my favourite little moments was that point about the app providing an objective read-out of the result, because this result “will be used to limit what people can do”. The certainty shared here about the test’s adoption and use case gives us a glimpse into the ongoing discussions with govt and regulators.
For KSH321.
Just finished listening to the presentation.
Wow. Alistair you are a genius. What a flawless presentation.
For any newbies on here or for any potential investors, you have to to listen to the presentation and also look at the slides.
Kindly provided by sharesgonesouth:
https://presentations.investormeetcompany.com/investor-meet-company/interim-results-for-the-6-months-ended-30-june-2020-2?bmid=be99f7fce6b6
Rapid Antigen Test (by Avacta) detects the presence of viral proteins and can provide screening test for the most infectious people.
PCR Test can detect small amounts of viral genetic material. So a test can be positive long after a person stops being infectious.
Antibody Tests detect the body's immune response to the virus and are not effective in the early part of the infection when people are most infectious.
Looks like we are going to have the Holy Grail of testing.
Especially when Sir Al said
"People may not know that there is a mutant of the Sars Cov 2 virus called D614G. This is a mutant spike protein and accounts for approx. 70% of the cases in USA and EU. It's a more infectious form of the virus and there is a bit of evidence that suggests antibodies against the normal virus are not effective against that mutant. The affimer agents (by Avacta) does bind this mutant virus spike protein."
Then there is preCISION. Most of us know about it now but it never fails to impress me when it is talked about.
Sir Al does not want to put any of the current projects in jeopardy by rushing things to the market. He wants the process to be done right. He wants the end results to be perfect because he is a perfectionist.
Chiron- As always, a brilliantly succinct presentation. But, please help me understand your prior made point about the C surface-protein being an important differentiator in determining "infectious" status. Hitherto, AS has only made reference to spike-proteins. Monkshood challenged me (quite rightly) about my reference to the C surface-protein and I am at a loss.
The reference by Sir John Bell to differentiating "infectious" people from "Covid in all its forms" (his words) seems important as, obviously, both epidemiologically and economically, identifying the "infectious" is paramount. If only identification of the spike protein is involved, how is this differentiation to be achieved? Thank you.
Thank you Chiron, excellent post. I was on the results presentation, but failed to take such notes as yours. Been in AVCT for many months, expect to remain an shareholder for many months to come too.
Hi Chiron, in what way may have Condor under delivered? The main issue seems to have been firstly time for Cytiva and secondly time for BBI to produce batch. Is it that Condor maybe didn't supply a template for this type of test early enough, resulting in Avacta having to adapt the kit?
Very interesting and valid points! Were you anything to do with Evan's Medical, Chiron, Novartis or Seqirus?
What I took away from today-I've put time stamps in brackets to where referenced in presentation-
-Expanding manufacturing looking at including SE Asia and OEM model(38,50)
-Detailed discussions with government(39,50)
-Clinical validation of LFT to be completed in Q4(slide30)
-Can detect mutated (most prevalent in EU/USA) strain of Covid spike protein as well(59,18)
-Considering foreign sites to trial AVA6000-very sensible for multiple reasons(16,44)
-Best performing ELISA test on market(19,58)
-No cross reactivity of affimers confirmed(21,50)
-BAMS will be fully clinically validated in Q4(slide 22)
-Confirmed my assertion (23rd Sept) CONDOR has under delivered(24,41) rather than product!
-LFT will identify infectious individuals rather than merely infected(28,50) stated this is governments desire too
-Professional use soon then at home use(31,53)
-Smartphone app in development for objective reading & record(33,55)
-Affimers bind to spike in a range of glycosylated states (58,24), how they flow along LFD is of academic interest rather than functional importance was inference
Now these are just a few of the take home messages. I was very impressed and expect great news in Q4. Undoubtedly there will be some share price mischief in next few weeks but I'm sticking to the facts as we know them today and holding tight!
All the best,
Chiron